Citing declining revenue, rising costs and “increasing external risks,” the BC Cancer Foundation announced Tuesday that it is ending its annual cycling fundraiser, the Tour de Cure.
“The decision to end the Tour de Cure was extremely difficult,” said Sarah Roth, the foundation’s president and CEO, in a news release.
“As both the CEO and a nine-year rider myself, I understand the deep, personal connection our community has to this annual fundraising event. It has been a powerful symbol of hope and determination.”
Formerly known as the Ride to Conquer Cancer, the tour began 16 years ago in 2009. Since then, it has raised more than $131 million in gross revenue, according to BC Cancer.
The foundation cited three “primary factors” for its decision to end the fundraiser. Those factors are:
- Rising costs, due to inflationary pressures and increased logistical expenses
- Declining net revenue and funds raised for cancer research, …